Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
13 Fevereiro 2024 - 10:30AM
Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading
radiopharmaceutical-focused company committed to enabling
clinicians to Find, Fight and Follow disease to deliver better
patient outcomes, today announced a collaboration agreement with a
National Institute on Aging (NIA)-sponsored study called the
Consortium for Clarity in ADRD Research Through Imaging (CLARiTI).
This agreement enables the consortium to use MK-6240, Lantheus’
clinical-stage F18-labeled Positron Emission Tomography (PET)
imaging agent, in its investigation of Alzheimer’s disease and
related dementias. MK-6240 targets aggregated tau protein in the
form of neurofibrillary tangles (NFTs) which are a hallmark of
several neurodegenerative diseases, including Alzheimer’s disease.
The CLARiTI study will involve all 37 Alzheimer’s Disease
Research Centers in the United States which will recruit 2,000
subjects and collect their imaging and blood-based biomarker data
to generate etiologic profiles for cases of mixed dementia.
“This study is designed to shed light on the complex interplay
of multiple pathologies contributing to dementia, ultimately
advancing our understanding and treatment of this devastating
condition,” said Sterling Johnson, PhD, Professor of Medicine,
University of Wisconsin School of Medicine and Public Health and
the CLARiTI study lead. “We are thrilled to partner with Lantheus
to use MK-6240 for tau PET imaging in this important study.”
“MK-6240 is poised to play a pivotal role in propelling
Alzheimer’s diagnosis and treatment research to new heights,” said
Jean-Claude Provost, MD, Chief Medical Officer, Lantheus. “This
agreement aligns with Lantheus’ purpose to actively cultivate
collaborations that empower researchers worldwide with essential
tools to accelerate clinical research and development of therapies.
In an era defined by an unprecedented number of Alzheimer’s
diagnoses, the CLARiTI study represents a significant milestone in
Alzheimer’s research, with the potential to change the trajectory
of this degenerative disease.”
About the CLARiTI StudyClarity in Alzheimer’s
Disease and Related Dementias Research Through Imaging (CLARiTI) is
a multi-site imaging observational study that will be conducted at
all 37 Alzheimer’s Disease Research Centers (ADRCs) in the United
States. The study will collect data about the presence, absence or
change in characteristic disease biomarkers in people who have
various types of dementia or are at risk of developing it. CLARiTI
is a five-year study that will enroll 2,000 subjects across the
U.S. Data generated from CLARiTI will be made available to the
scientific community through the National Alzheimer's Coordinating
Center, and biological samples will be analyzed and made available
through the National Centralized Repository for Alzheimer’s Disease
and Related Dementias.
Please visit https://naccdata.org/nacc-collaborations/clariti
for more information about the study.
About Alzheimer’s Disease and
DementiaAlzheimer’s disease is a progressive degenerative
brain disease and the most common form of dementia. Dementia is the
loss of cognitive functioning and behavioral abilities to such an
extent that it interferes with a person’s daily life and
activities. Dementia is not a specific disease; it describes a
group of symptoms that often has a mixture of etiologies. It is
estimated that 6.7 million Americans age 65 and older are currently
living with Alzheimer’s dementia. As the population ages, it is
projected that by 2050, this number may grow to 12.7 million.1
About Lantheus Lantheus is the leading
radiopharmaceutical-focused company, delivering life-changing
science to enable clinicians to Find, Fight and Follow disease to
deliver better patient outcomes. Headquartered in Massachusetts
with offices in New Jersey, Canada and Sweden, Lantheus has been
providing radiopharmaceutical solutions for more than 65 years. For
more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary
StatementsThis press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, that are subject to risks and
uncertainties and are made pursuant to the safe harbor provisions
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements may be identified by their use of terms
such as “designed,” “poised,” “potential,” “will” and other similar
terms. Such forward-looking statements are subject to risks and
uncertainties that could cause actual results to materially differ
from those described in the forward-looking statements. Readers are
cautioned not to place undue reliance on the forward-looking
statements contained herein, which speak only as of the date
hereof. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by law.
Risks and uncertainties that could cause the Company’s actual
results to materially differ from those described in the
forward-looking statements are discussed in the Company’s filings
with the Securities and Exchange Commission (including those
described in the Risk Factors section in the Company’s Annual
Report on Form 10-K and its Quarterly Reports on Form 10-Q).
1Alzheimer’s Association. 2023 Alzheimer’s Disease Facts and
Figures. Alzheimer’s Dement 2023;19(4). DOI 10.1002/alz.13016.
Contacts:
LantheusMark KinarneyVice President, Investor
Relations 978-671-8842ir@lantheus.com
Melissa DownsSenior Director, External Communications
646-975-2533media@lantheus.com
Lantheus (NASDAQ:LNTH)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Lantheus (NASDAQ:LNTH)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024